Savara Inc

Research Savara Inc (SVRA) on Bullrun: market cap USD 1.24B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSVRA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.24B
• Financial periodFY2025
• Net income-USD 118.84M
• Free cash flow-USD 101.06M

Valuation Snapshot

latest market cap is USD 1.24B.

About Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Frequently asked questions

What is Savara Inc's market cap?

Savara Inc's market capitalization is USD 1.24B.

What does Savara Inc do?

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of...